Seres Therapeutics is laying off approximately 30% of its roughly 103-person workforce as part of a pipeline refocusing initiative. The company is pausing investment in its Phase 2 SER-155 study and shifting focus to earlier-stage programs including SER-603 for inflammatory and immune indications.
